We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 108.00 | 0.90% | 12,170.00 | 12,172.00 | 12,174.00 | 12,266.00 | 12,054.00 | 12,194.00 | 871,104 | 16:35:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.69 | 188.69B |
From May 2019 to May 2024
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has been approved in the European Union to treat type-2 diabetes.
The drug maker said that Qtrilmet, a modified-release tablet to improve glycaemic control in adults with type-2 diabetes, was approved by the European Commission, based on data from five Phase 3 trials.
The drug was approved in the U.S. in May under the name Qternmet XR.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 15, 2019 02:26 ET (07:26 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
